Literature DB >> 8317125

Antiplatelet therapy--Part I.

S H Goodnight1, B M Coull, J H McAnulty, L M Taylor.   

Abstract

We summarize current information about aspirin and other antiplatelet drugs in patients with cardiac and vascular disease. For each indication, we briefly summarize the rationale for the use of antiplatelet therapy and describe the findings of relevant clinical trials. We propose recommendations for the use of these agents in clinical practice. Part I covers the use of antiplatelet therapy for the primary and secondary prevention of myocardial infarction, coronary thrombolysis, unstable and chronic stable angina, and coronary artery-saphenous vein bypass grafts. In part II we review the use of antiplatelet agents in coronary angioplasty, atrial fibrillation, artificial cardiac valves, stroke, and peripheral vascular disease.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8317125      PMCID: PMC1022066     

Source DB:  PubMed          Journal:  West J Med        ISSN: 0093-0415


  76 in total

Review 1.  An apple a day or an aspirin a day?

Authors:  J E Dalen
Journal:  Arch Intern Med       Date:  1991-06

2.  Aspirin, the ageless remedy?

Authors:  J A Mills
Journal:  N Engl J Med       Date:  1991-10-31       Impact factor: 91.245

3.  Thrombocytes and coronary heart disease.

Authors:  L Wilhelmsen
Journal:  Circulation       Date:  1991-08       Impact factor: 29.690

4.  Blood platelet count and function are related to total and cardiovascular death in apparently healthy men.

Authors:  E Thaulow; J Erikssen; L Sandvik; H Stormorken; P F Cohn
Journal:  Circulation       Date:  1991-08       Impact factor: 29.690

5.  Influence of platelet size on outcome after myocardial infarction.

Authors:  J F Martin; P M Bath; M L Burr
Journal:  Lancet       Date:  1991-12-07       Impact factor: 79.321

6.  A prospective study of aspirin use and primary prevention of cardiovascular disease in women.

Authors:  J E Manson; M J Stampfer; G A Colditz; W C Willett; B Rosner; F E Speizer; C H Hennekens
Journal:  JAMA       Date:  1991 Jul 24-31       Impact factor: 56.272

7.  Evaluation of thromboxane production and complement activation during myocardial ischemia in patients with angina pectoris.

Authors:  G Montalescot; G Drobinski; J Maclouf; F Maillet; J Salloum; A Ankri; M Kazatchkine; L Eugène; D Thomas; Y Grosgogeat
Journal:  Circulation       Date:  1991-11       Impact factor: 29.690

8.  Suppression of thromboxane A2 but not of systemic prostacyclin by controlled-release aspirin.

Authors:  R J Clarke; G Mayo; P Price; G A FitzGerald
Journal:  N Engl J Med       Date:  1991-10-17       Impact factor: 91.245

9.  Starting aspirin therapy after operation. Effects on early graft patency. Department of Veterans Affairs Cooperative Study Group.

Authors:  S Goldman; J Copeland; T Moritz; W Henderson; K Zadina; T Ovitt; K B Kern; G Sethi; G V Sharma; S Khuri
Journal:  Circulation       Date:  1991-08       Impact factor: 29.690

10.  Aspirin (75 mg/day) after an episode of unstable coronary artery disease: long-term effects on the risk for myocardial infarction, occurrence of severe angina and the need for revascularization. Research Group on Instability in Coronary Artery Disease in Southeast Sweden.

Authors:  L C Wallentin
Journal:  J Am Coll Cardiol       Date:  1991-12       Impact factor: 24.094

View more
  1 in total

1.  Use of antiplatelet agents in the management of thrombotic disorders.

Authors:  L A Harker
Journal:  West J Med       Date:  1993-04
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.